Insights

Benchmark International Successfully Facilitated the Transaction Between Molzym GmbH & Co. KG and Bruker Daltronics GmbH & Co. KG

November 20, 2025

Benchmark International is pleased to announce the 100% acquisition of Molzym GmbH & Co. KG by Bruker Daltronics GmbH & Co. KG.

Molzym GmbH & Ko. KG, based in Bremen, Germany, is a leading company in biological research and the diagnosis of infectious agents, focusing on the development of new methods and products for the molecular detection of infectious diseases caused by bacteria and fungi. Founded by Prof. Lorenz, the company now sells its kits and reagents in over 30 countries and employs a team of 26 people.

Bruker Daltronics GmbH & Co. KG, headquartered in Bremen, Germany, the company employs over 9,700 people worldwide and provides high-performance scientific instruments and analytical and diagnostic solutions for researching biological and chemical processes at the molecular, cellular and microscopic levels.

Your Path to a Successful Sale Begins Here.

With the acquisition of Molzym, Bruker aims to strengthen its presence in biological research and the diagnosis of infectious diseases. The expertise, technology and good reputation are expected to help Bruker continue to grow.

“We are extremely pleased with this successful transaction. In Bruker, we have won a strong and experienced partner. We would also like to express our sincere thanks to everyone involved for their support during the process.” - Dr. Michael Lustig, Managing Director, Molzym GmbH & Co. KG

Benchmark International played a key role in managing the transaction process, from the initial offer through to completion. The team successfully guided the client through the entire process, including a thorough due diligence, ensuring a balanced structure that aligned with the strategic objectives of both parties.

“We are proud to have supported Molzym’s shareholders in securing this strategic acquisition by Bruker. This partnership combines two highly respected biotechnology innovators and positions both companies for continued advancement in molecular diagnostics and life sciences.” - Malte Bockholt, Transaction Lead, Benchmark International 

Schedule a Call

Americas: Sam Smoot at +1 (813) 898 2350 / [email protected]

Europe: Michael Lawrie at +44 (0) 161 359 4400 / [email protected]

Africa: Anthony McCardle at +27 21 300 2055 / [email protected] 

 

ABOUT BENCHMARK INTERNATIONAL:

Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled transactions across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network, as well as the #1 Sell-side Privately Owned M&A Advisor in the World by PitchBook’s and LSEG's Global League Tables.

The content provided by Benchmark International, including articles, blog posts, videos, and other media, is for general informational purposes only and does not constitute legal, financial, investment, or business advice. While we strive for accuracy, the information may be based on third-party sources, market trends, and evolving industry data that are not independently verified or guaranteed to be current or complete. Any opinions expressed are those of the authors and do not necessarily reflect the views of Benchmark International. Market trends, forecasts, and forward-looking statements are inherently uncertain and subject to change. Nothing in our content should be relied upon as a substitute for personalized advice from qualified professionals. Benchmark International disclaims all liability for any loss or damage resulting from reliance on this content. Always consult with appropriate experts before making business decisions.

Share This Post
Categories

Get These Insights Delivered Directly To Your Email

Explore our curated collection today and stay ahead of the curve in M&A.

Publicaciones relacionadas
Cómo atraer a los compradores adecuados: qué hace que un Negocio Sea más valiosoEn el dinámico mundo de las fusiones y adquisiciones (M&A), vender su empresa es un proceso complejo que requiere planificación estratégica, experiencia en valoraciones y comprensión de lo que buscan los compradores potenciales. Los compradores e inversores se mueven por diversos motivos, como la aceleración del crecimiento, la expansión del mercado y la diversificación de la cartera. Atraer con éxito a los compradores adecuados puede influir significativamente en el precio de venta y en el éxito global de la transacción. Pero, ¿qué es exactamente lo que puede hacer que su empresa sea más valiosa y atractiva para los posibles compradores? Exploremos los factores clave que pueden aumentar el atractivo de su empresa en las fusiones y adquisiciones y cómo puede posicionar su negocio para conseguir el máximo atractivo.Por qué los procesos de venta con múltiples partes son una oportunidad para los compradoresPara muchos adquirentes, las palabras "proceso competitivo " siguen teniendo un trasfondo de fricción. Sugieren distracción, expectativas infladas, presión innecesaria y el riesgo de ser utilizados como una tensión de precios en lugar de una contraparte seria. Sin embargo, esta interpretación a menudo pasa por alto la realidad más profunda. Para la mayoría de los propietarios de empresas, en particular los fundadores y los operadores con muchos años de experiencia, un proceso de venta con varias partes no es un acto de agresión; es un acto de responsabilidad: para con ellos mismos, para con la empresa y para con el comprador.
¿No encuentras lo que buscas?
¿Está listo para sumergirse en nuestro contenido destacado sobre fusiones y adquisiciones y obtener información valiosa para su negocio?